Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1599440-13-7
2. Mc-ggfg-dxd(1)
3. 5seb972co4
4. N-((s)-10-benzyl-1-(((1s,9s)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1h,12h-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-yl)-6-(2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)hexanamide
5. 6-(2,5-dioxopyrrol-1-yl)-n-[2-[[2-[[(2s)-1-[[2-[[2-[[(10s,23s)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]amino]-2-oxoethoxy]methylamino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]hexanamide
6. Deruxtecan [usan]
7. Unii-5seb972co4
8. Maaa-1162a
9. Schembl17003548
10. Ex-a4318
11. Hy-13631e
12. Deruxtecan Pyrrole-2,5-dione
13. Akos040741623
14. At21794
15. Ms-31882
16. Cs-0045125
17. A937678
18. N-((s)-5-(2-amino-2-oxoethyl)-7-benzyl-1-(((1s,9s)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1h,12h-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12-tetraoxo-3-oxa-5,8,11-triazatridecan-13-yl)-6-(2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)hexanamide
19. N-(6-(2,5-dihydro-2,5-dioxo-1h-pyrrol-1-yl)-1-oxohexyl)glycylglycyl-l-phenylalanyl-n-((2-(((1s,9s)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1h,12h-benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinolin-1-yl)amino)-2-oxoethoxy
20. N-(6-(2,5-dihydro-2,5-dioxo-1h-pyrrol-1-yl)-1-oxohexyl)glycylglycyl-l-phenylalanyl-n-((2-(((1s,9s)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1h,12h-benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinolin-1-yl)amino)-2-oxoethoxy)methyl)glycinamide
Molecular Weight | 1034.1 g/mol |
---|---|
Molecular Formula | C52H56FN9O13 |
XLogP3 | -0.4 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 22 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 301 |
Heavy Atom Count | 75 |
Formal Charge | 0 |
Complexity | 2360 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
56
PharmaCompass offers a list of Deruxtecan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Deruxtecan manufacturer or Deruxtecan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Deruxtecan manufacturer or Deruxtecan supplier.
PharmaCompass also assists you with knowing the Deruxtecan API Price utilized in the formulation of products. Deruxtecan API Price is not always fixed or binding as the Deruxtecan Price is obtained through a variety of data sources. The Deruxtecan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Deruxtecan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deruxtecan, including repackagers and relabelers. The FDA regulates Deruxtecan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deruxtecan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Deruxtecan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Deruxtecan supplier is an individual or a company that provides Deruxtecan active pharmaceutical ingredient (API) or Deruxtecan finished formulations upon request. The Deruxtecan suppliers may include Deruxtecan API manufacturers, exporters, distributors and traders.
click here to find a list of Deruxtecan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Deruxtecan DMF (Drug Master File) is a document detailing the whole manufacturing process of Deruxtecan active pharmaceutical ingredient (API) in detail. Different forms of Deruxtecan DMFs exist exist since differing nations have different regulations, such as Deruxtecan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Deruxtecan DMF submitted to regulatory agencies in the US is known as a USDMF. Deruxtecan USDMF includes data on Deruxtecan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Deruxtecan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Deruxtecan suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Deruxtecan Drug Master File in Japan (Deruxtecan JDMF) empowers Deruxtecan API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Deruxtecan JDMF during the approval evaluation for pharmaceutical products. At the time of Deruxtecan JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Deruxtecan suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Deruxtecan as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Deruxtecan API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Deruxtecan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Deruxtecan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Deruxtecan NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Deruxtecan suppliers with NDC on PharmaCompass.
Deruxtecan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deruxtecan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deruxtecan GMP manufacturer or Deruxtecan GMP API supplier for your needs.
A Deruxtecan CoA (Certificate of Analysis) is a formal document that attests to Deruxtecan's compliance with Deruxtecan specifications and serves as a tool for batch-level quality control.
Deruxtecan CoA mostly includes findings from lab analyses of a specific batch. For each Deruxtecan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deruxtecan may be tested according to a variety of international standards, such as European Pharmacopoeia (Deruxtecan EP), Deruxtecan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deruxtecan USP).